Cartesian Therapeutics, Inc.

General ticker "RNAC" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $237.7M (TTM average)

Cartesian Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -18.9%.

Estimated limits based on current volatility of 3.5%: low 6.20$, high 6.65$

Factors to consider:

  • Earnings expected soon, date: 2026-05-14 bmo
  • Total employees count: 66 as of 2024
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [4.24$, 11.56$]
  • 2026-12-31 to 2027-12-31 estimated range: [4.52$, 11.85$]

Financial Metrics affecting the RNAC estimates:

  • Positive: with PPE of -2.4 at the end of fiscal year the price was neutral
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -41.13 <= 0.07
  • Positive: Interest expense per share per price, % of 0 <= 0.01
  • Positive: -4.45 < Investing cash flow per share per price, % of -3.03
  • Negative: Shareholder equity ratio, % of -42.59 <= 19.49

Similar symbols

Short-term RNAC quotes

Long-term RNAC plot with estimates

Financial data

YTD 2024-12-31 2025-12-31
Operating Revenue $38.91MM $2.80MM
Operating Expenses $82.81MM $89.50MM
Operating Income $-43.90MM $-86.70MM
Non-Operating Income $-33.24MM $-52.79MM
R&D Expense $45.10MM $58.03MM
Income(Loss) $-77.14MM $-139.50MM
Taxes $0.29MM $-9.19MM
Profit(Loss)* $-77.42MM $-130.30MM
Stockholders Equity $-6.80MM $-126.24MM
Assets $435.02MM $296.41MM
Operating Cash Flow $-23.67MM $-73.94MM
Capital expenditure $9.09MM $5.45MM
Investing Cash Flow $-8.74MM $-5.45MM
Financing Cash Flow $168.43MM $-8.05MM
Earnings Per Share** $-2.99 $-5.02

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.